Scarica l'app Stockscreener
44.79
1.99%
-0.91
Dopo l'orario di chiusura:
45.00
0.21
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$45.70
Aprire:
$46.23
Volume 24 ore:
744.19K
Relative Volume:
0.89
Capitalizzazione di mercato:
$2.51B
Reddito:
$665.13M
Utile/perdita netta:
$64.50M
Rapporto P/E:
39.15
EPS:
1.1442
Flusso di cassa netto:
$185.87M
1 W Prestazione:
+0.79%
1M Prestazione:
-13.18%
6M Prestazione:
+34.91%
1 anno Prestazione:
+24.00%
Intervallo 1D:
$44.76
$46.47
Intervallo di 1 settimana:
$44.05
$46.47
Portata 52W:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
44.79 | 2.62B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Why Supernus Pharmaceuticals Inc. stock could benefit from AI revolutionQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com
How Supernus Pharmaceuticals Inc. stock benefits from tech adoption2025 Pullback Review & Real-Time Volume Analysis Alerts - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.Sell Signal & Expert Approved Trade Ideas - newser.com
Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Measuring Supernus Pharmaceuticals Inc.’s beta against major indices2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Raising 2025 Revenue Guidance Despite Net Losses - simplywall.st
Supernus at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Australia
SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus - TradingView
What analysts say about Supernus Pharmaceuticals Inc stockTechnical Breakout Signals & Free Powerful Profit Generation - earlytimes.in
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.2025 Macro Impact & Technical Confirmation Alerts - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementJobs Report & Weekly Momentum Stock Picks - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Why Supernus Pharmaceuticals Inc. stock remains undervaluedEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London - The Manila Times
Supernus (NASDAQ: SUPN) fireside chat Nov. 17 at 9:30 a.m. EST; webcast available - Stock Titan
5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2025 Earnings Call Transcript - MSN
The Technical Signals Behind (SUPN) That Institutions Follow - news.stocktradersdaily.com
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.17%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):